FY2026 EPS Estimates for Evaxion A/S Decreased by Analyst

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) – Equities researchers at HC Wainwright dropped their FY2026 earnings per share estimates for Evaxion A/S in a research report issued to clients and investors on Friday, August 21st. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($2.00) per share for the year, down from their prior estimate of ($0.50). The consensus estimate for Evaxion A/S’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Evaxion A/S’s FY2027 earnings at $0.00 EPS, FY2028 earnings at $1.50 EPS, FY2029 earnings at $2.50 EPS and FY2030 earnings at $3.00 EPS.

Separately, Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Evaxion A/S Stock Performance

NASDAQ EVAX opened at $3.40 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. Evaxion A/S has a 1-year low of $2.52 and a 1-year high of $12.15. The business has a 50 day simple moving average of $3.13 and a two-hundred day simple moving average of $3.56. The stock has a market capitalization of $28.36 million, a PE ratio of -2.81 and a beta of 0.29.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EVAX. Rathbones Group PLC purchased a new position in Evaxion A/S in the first quarter worth about $170,000. Renaissance Technologies LLC purchased a new stake in Evaxion A/S during the first quarter valued at approximately $146,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Evaxion A/S during the first quarter valued at approximately $112,000. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S in the 4th quarter valued at approximately $72,000. Finally, Wesbanco Bank Inc. purchased a new position in shares of Evaxion A/S in the 4th quarter worth approximately $48,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.